舒尼替尼对裸鼠肾癌个性化治疗的实验研究(3)
[4] 刘京，赵正焱.舒尼替尼对转移性肾肿瘤的安全性和效果观察[J].中国医药指南，2011，9(9)：265-267.
[5] Cumming SM，Higginbott MK，Mccurk CJ，et al. XPA versus ERCCl as chemosensitising agents to cisp latin and mitomycin C in prostate cancer cells：role of ERCCl in homologous recombination repair [J]. Biochem Pharmacol，2006，72(2)：166-175.
[6] Lam JS，Shvarts O，Leppert JT. Renal cell carcinoma 2005：new frontiers in staging，prognostication and targeted molecular therapy [J]. J Urol，2005，173(6)：1853-1862.
[7] Arora A，Scholar EM. Role of tyrosine kinase inhibitors in cancer Therapy [J]. J Pharmacol Exp Ther，2005，315(3)：971-979.
[8] Klatte T，Pantucka J，Riggss B，et al. Prognostic factorsfor renal cell carcinoma with tumor thrombus extension [J]. J Urol，2011，178(4)：11892-11950.
[9] Rogiers A，Wolter P，Opde B，et al. Shrinkage of thyroid volume in Sunitinib-treated patientswith renal-cell carcino-ma：a potential marker of irreversible thyroid dysfunction [J]. Thyroid，2010，20(3)：317-322.
(收稿日期：2012-02-16 本文编辑：卫 轲), 百拇医药(孙飞达 王东文 白淘 茹峰 张雪峰)
[5] Cumming SM，Higginbott MK，Mccurk CJ，et al. XPA versus ERCCl as chemosensitising agents to cisp latin and mitomycin C in prostate cancer cells：role of ERCCl in homologous recombination repair [J]. Biochem Pharmacol，2006，72(2)：166-175.
[6] Lam JS，Shvarts O，Leppert JT. Renal cell carcinoma 2005：new frontiers in staging，prognostication and targeted molecular therapy [J]. J Urol，2005，173(6)：1853-1862.
[7] Arora A，Scholar EM. Role of tyrosine kinase inhibitors in cancer Therapy [J]. J Pharmacol Exp Ther，2005，315(3)：971-979.
[8] Klatte T，Pantucka J，Riggss B，et al. Prognostic factorsfor renal cell carcinoma with tumor thrombus extension [J]. J Urol，2011，178(4)：11892-11950.
[9] Rogiers A，Wolter P，Opde B，et al. Shrinkage of thyroid volume in Sunitinib-treated patientswith renal-cell carcino-ma：a potential marker of irreversible thyroid dysfunction [J]. Thyroid，2010，20(3)：317-322.
(收稿日期：2012-02-16 本文编辑：卫 轲), 百拇医药(孙飞达 王东文 白淘 茹峰 张雪峰)